+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Vascular endothelial growth factor as a target for antiangiogenic therapy



Vascular endothelial growth factor as a target for antiangiogenic therapy



Journal of Clinical Oncology 18(21 Suppl): 45s-46s




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 036031930

Download citation: RISBibTeXText

PMID: 11060326


Related references

Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Clinical Advances in Hematology and Oncology 1(1): 41-48, 2003

Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation 130(13): 1072-1080, 2014

Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Advances in Oto-Rhino-Laryngology 62: 103-120, 2005

Antiangiogenic therapy of tumors using a vascular endothelial growth factor Diphtheria toxin conjugate. European Journal of Clinical Investigation 28(Suppl. 1): A42, 1998

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Experimental Biology and Medicine 235(1): 3-9, 2010

Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America 92(14): 6374-6378, 1995

Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Research 59(21): 5412-5416, 1999

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews 2009(4): Cd007419, 2009

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews 12: Cd007419, 2012

Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 112(9): 1347-1352, 2005

Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Canadian Journal of Cardiology 30(5): 534-543, 2014

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008(2): Cd005139, 2008

Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Human Gene Therapy 10(7): 1117-1128, 1999

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology 20(21): 4368-4380, 2002

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets 5(4): 229-248, 2005